What You Should Know:
– Elucid, a company pioneering AI-powered medical technology for cardiovascular disease (CVD), has named Dr. Kelly Huang, PhD as its new President and Chief Executive Officer (CEO). Dr. Huang’s appointment comes at a pivotal moment for Elucid, as they prepare for the commercial launch of their groundbreaking PlaqueIQ software.
– Dr. Huang brings a wealth of experience in commercializing impactful medical technologies. He previously held leadership positions at Cardea Bio, L-Nutra, and Obalon Therapeutics, demonstrating a successful track record in market development for innovative medical products.
– PlaqueIQ is a first-of-its-kind software, utilizing FDA-cleared computed tomography angiography (CTA) to analyze and characterize plaque buildup in arteries. This non-invasive technique is validated against the gold standard of ground truth histology, providing physicians with a more objective and accurate assessment of cardiovascular risk.
